Maple Epithalon (also written as Epitalon) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly, originally derived from bovine pineal gland extracts at the St. Petersburg Institute of Bioregulation and Gerontology. It is the most extensively studied pineal bioregulatory peptide in preclinical aging research, with documented effects on telomerase reactivation, melatonin biosynthesis, chromatin remodeling, and antioxidant enzyme induction across cell culture, rodent, primate, and limited human models. Researchers investigating peptide-mediated geroprotection increasingly reference Epithalon’s multi-pathway mechanism profile, which spans at least five of the recognized hallmarks of aging.
The peptide’s research trajectory spans more than three decades. Vladimir Khavinson and colleagues at the St. Petersburg Institute first characterized the biological activity of Epithalamin, a crude pineal extract, in the 1970s and 1980s. The synthetic tetrapeptide AEDG (Epithalon) was subsequently identified as the minimal active sequence responsible for the extract’s geroprotective properties. In 2017, Khavinson and Kopylov confirmed the presence of the AEDG sequence in native pineal gland tissue using mass spectrometry, establishing its endogenous origin rather than purely synthetic provenance (Khavinson et al., Bulletin of Experimental Biology and Medicine, 2017, 164:41-43). This finding validated decades of research predicated on the assumption that Epithalon represented a naturally occurring regulatory peptide.
Molecular Identity and Physicochemical Properties
Epithalon’s molecular formula is C14H22N4O9, with a molecular weight of 390.35 g/mol and a CAS number of 307297-39-8. The tetrapeptide carries a net negative charge at physiological pH due to the glutamic acid and aspartic acid residues, which influences both its solubility profile and its interaction with positively charged DNA-binding domains. The compound is freely soluble in aqueous buffers and is typically supplied as either the free-base form or as acetate and trifluoroacetate (TFA) salt variants for research applications.
Structurally, the peptide’s small size (just four amino acids) creates both advantages and constraints for research use. The compact structure enables nuclear penetration and direct DNA interaction, as demonstrated by fluorescence microscopy studies showing Epithalon accumulation within HeLa cell nuclei (Fedoreyeva et al., Biochemistry Moscow, 2011, 76:1210-1219). However, like most short peptides, it is susceptible to enzymatic degradation by gastrointestinal proteases, which has driven the predominant use of subcutaneous injection in published studies. Researchers have explored dendrimer conjugation to improve membrane penetration and bioavailability, though these approaches remain at the in silico and early in vitro stage (Fatullaev et al., International Journal of Biology and Biomedical Engineering, 2022, 16:73-81).
Telomerase Reactivation and Telomere Elongation
The most frequently cited mechanism of Epithalon involves its capacity to reactivate telomerase, the ribonucleoprotein enzyme complex responsible for maintaining the repetitive TTAGGG sequences that cap chromosome ends. Telomere attrition during each cell division cycle represents a fundamental constraint on replicative lifespan, and the progressive shortening of telomeres is mechanistically linked to cellular senescence, tissue dysfunction, and organismal aging.
Khavinson, Bondarev, and Butyugov published the landmark study on Epithalon’s telomerase activity in 2003 in the Bulletin of Experimental Biology and Medicine (135:590-592). Using the Telomeric Repeat Amplification Protocol (TRAP) assay, they demonstrated that Epithalon treatment of human fetal lung fibroblast cultures (strain 602/17) induced expression of the hTERT catalytic subunit, increased measurable telomerase enzymatic activity, and produced telomere elongation during the G1 phase of the cell cycle. Critically, untreated control fibroblasts entered replicative senescence at approximately passage 34, while Epithalon-treated cultures continued dividing beyond passage 44, surpassing the Hayflick limit by more than 10 additional population doublings. The treated cells maintained youthful morphology and gene expression profiles throughout the extended culture period.
A 2019 study by Khavinson, Pendina, and colleagues extended these findings to PHA-stimulated human blood lymphocytes from adult donors aged 25 to 88 years (Bulletin of Experimental Biology and Medicine, 2019, 168:141-144). Epithalon treatment induced telomerase component expression and increased enzymatic activity across age groups, with some samples showing telomere length increases averaging 33.3%. The variability between individuals was notable and likely reflects differences in baseline telomerase expression, donor age, and cellular metabolic state.
More recently, a 2025 preprint by Al-dulaimi, Thomas, Matta, and Roberts reported that Epithalon increased telomere length in multiple human cell lines, operating through either canonical telomerase upregulation or activation of the Alternative Lengthening of Telomeres (ALT) pathway depending on cell type (Research Square, rs-7066545/v1). This dual-mechanism finding is significant because ALT activation has been previously associated primarily with certain cancer cell types and suggests Epithalon’s telomere effects may be more complex than simple hTERT induction.
In reproductive biology, Ullah and colleagues (2025) demonstrated that Epithalon activated telomerase and enhanced TERT protein localization in bovine cumulus-oocyte complexes, improving oocyte maturation rates and post-thaw embryo development (Life Sciences, 2025, 362:123381). This work suggests potential applications in fertility research and cryopreservation protocols beyond the aging context.
Epigenetic Modulation and Chromatin Remodeling
Epithalon’s mechanism extends beyond direct telomerase activation into epigenetic territory. The peptide demonstrates selective binding to DNA regions enriched in CAG and ATTTC repeat motifs, which are concentrated within promoter regions of the telomerase gene and other transcriptionally regulated loci (Fedoreyeva et al., 2011). This promoter-level interaction positions Epithalon as a transcriptional modulator rather than a simple enzyme activator.
In aged human lymphocyte cultures, Epithalon reversed age-associated heterochromatinization, the progressive condensation of chromatin that silences gene expression in aging cells. Khavinson and colleagues at the Georgian Academy of Sciences showed that the peptide increased chromatin plasticity, making previously silenced DNA regions accessible to transcription factors (Khavinson et al., Neuro Endocrinology Letters, 2003, 24:329-333). In silico molecular docking studies further revealed high binding affinity for histone subtypes H1/3 and H1/6, both of which regulate chromatin compaction and accessibility (Khavinson et al., Molecules, 2020, 25:609).
The antimutagenic dimension of Epithalon’s epigenetic activity was characterized in studies exposing human cells to heavy metals (zinc, cobalt, nickel) known to induce DNA strand breaks and chromosomal instability. Epithalon significantly reduced the extent of genotoxic damage in these models (International Journal of Peptide Research and Therapeutics, 2022). Separately, biophysical studies showed that Epithalon lowered the melting temperature of DNA by 41 degrees Celsius in vitro, indicating a conformational shift in duplex architecture that may facilitate transcription while preventing the rigid chromatin state characteristic of aged cells (Solovyev et al., International Journal of Biological Macromolecules, 2015, 78:39-45).
Melatonin Biosynthesis and Circadian Rhythm Restoration
Given Epithalon’s origin as a pineal-derived peptide, its effects on melatonin synthesis represent a mechanistically coherent research finding rather than a surprising secondary effect. Melatonin production declines by up to 75% across the human lifespan, and this decline correlates with disrupted circadian signaling, impaired immune surveillance, reduced antioxidant capacity, and accelerated biological aging.
In rat pinealocyte cultures, Khavinson and colleagues demonstrated that Epithalon upregulated both AANAT (arylalkylamine N-acetyltransferase) and pCREB (phosphorylated cAMP response element-binding protein), the two key enzymes in the melatonin biosynthetic pathway (Bulletin of Experimental Biology and Medicine, 2012, 153:255-258). The effect was dose-dependent but also exhibited non-linear behavior at higher concentrations, where overstimulation appeared to suppress rather than enhance melatonin output, underscoring the importance of concentration optimization in research protocols.
In aged Rhesus monkeys (20-26 years), Goncharova, Khavinson, and Lapin showed that Epithalon administration restored the evening melatonin peak toward levels characteristic of younger animals while simultaneously normalizing cortisol secretion patterns in a time-of-day-dependent manner (Bulletin of Experimental Biology and Medicine, 2001, 131:394-396). The dual hormonal normalization suggests that Epithalon’s circadian effects operate upstream of individual hormone axes, potentially at the level of pineal gland function itself.
A randomized study in 75 women evaluated sublingual Epithalon at 0.5 mg/day for 20 days against placebo and untreated controls. Urinary 6-sulfatoxymelatonin (the primary melatonin metabolite) increased 1.6-fold in the Epithalon group. At the genomic level, the peptide modulated expression of core circadian genes in leukocytes: Clock expression decreased 1.8-fold, Cry2 expression doubled, and Csnk1e expression in lymphocytes decreased 2.1-fold, all reaching statistical significance. These findings indicate effects beyond simple melatonin boosting, suggesting genuine circadian gene re-entrainment.
Epithalon also appears to protect pineal tissue from age-related structural decline. In aged human pinealocyte cultures, the peptide selectively safeguarded cells from degenerative changes and preserved mitochondrial staining patterns (Ivko et al., Advances in Gerontology, 2021, 11:261-267). This tissue-protective effect may explain how Epithalon sustains its chronobiotic activity rather than simply providing a transient hormonal stimulus.
Antioxidant Defense and Oxidative Stress Reduction
Epithalon activates the Keap1/Nrf2 signaling axis, a master regulator of cellular redox homeostasis. Through this pathway, the peptide upregulates expression of superoxide dismutase (SOD-1), catalase, and NAD(P)H quinone dehydrogenase 1 (NQO1) in human cell models. In skin fibroblast cultures, Gutop and colleagues demonstrated that Epithalon-treated cells showed reduced intracellular reactive oxygen species, improved mitochondrial membrane potential, and protection against senescence-associated damage markers (Advances in Gerontology, 2022, 12:143-148).
In human gingival and periodontal stem cells, the peptide significantly reduced expression of the senescence markers p16 and p21, decreased ROS levels, and preserved mitochondrial function under oxidative stress conditions (Stem Cell Reviews and Reports, 2019). In mouse oocyte models, Epithalon reduced levels of gamma-H2AX, a specific marker of DNA double-strand breaks, and prevented apoptosis in post-ovulatory aged cells (Aging, 2023).
The antioxidant effects extend to whole-organism models. In Drosophila melanogaster, Epithalon reduced both mitochondrial and cytosolic ROS along with lipid peroxidation markers including Schiff bases and hydroperoxides. These biochemical improvements translated into enhanced locomotor activity and measurable lifespan extension (Khavinson et al., Mechanisms of Ageing and Development, 2000, 120:141-149). In CBA mice, long-term Epithalon administration preserved brain and liver mitochondrial ultrastructure following irradiation, indicating organ-level structural protection (Anisimov et al., Mechanisms of Ageing and Development, 2001, 122:41-68).
Preclinical Lifespan and Tumor Incidence Data
Multiple animal models have generated lifespan data for Epithalon, though the consistency and independence of these findings require careful evaluation. In female CBA mice, Anisimov and colleagues reported that Epithalon increased mean lifespan by approximately 12.3% while reducing spontaneous tumor incidence by roughly 30% (2001). In Drosophila melanogaster, Khavinson reported lifespan extensions of 11-16% depending on the strain and dosing protocol (2000). In female rats, epithalamin (the crude pineal extract from which Epithalon was derived) increased mean lifespan by 24% in earlier studies.
The tumor suppression data is particularly notable. In HER-2/neu transgenic mice engineered to spontaneously develop mammary adenocarcinomas, Epithalon reduced overall tumor incidence, delayed tumor onset, and decreased tumor multiplicity per animal. The peptide also downregulated HER-2/neu gene expression, likely through chromatin-level transcriptional regulation (Anisimov et al., International Journal of Cancer, 2002, 101:7-10). In a chemically induced colon cancer model using 1,2-dimethylhydrazine (DMH), Epithalon reduced tumor burden across preventive, concurrent, and post-exposure treatment windows (Cancer Letters, 2002, 183:1-8).
In senescence-accelerated SAMP mice, Epithalon stabilized chromatin structure and reduced the incidence of chromosomal aberrations that predispose to malignant transformation (Rosenfeld et al., Bulletin of Experimental Biology and Medicine, 2002, 133:274-276).
Immunomodulatory Effects
Epithalon’s immune effects center on interleukin-2 (IL-2) regulation and T-cell subset rebalancing rather than broad immunostimulation. In human splenocyte cultures, IL-2 mRNA levels rose significantly within five hours of Epithalon exposure (Kazakova et al., Bulletin of Experimental Biology and Medicine, 2002, 133:614-616). In aged rodents, both intranasal and intramuscular administration elevated IL-2 expression specifically in hypothalamic nuclei, suggesting neuroimmune integration rather than peripheral immune activation alone (Kazakova et al., 2005; Barabanova et al., 2006).
In aged mice, Epithalon increased CD4+ T-cell populations in bone marrow while preserving CD8+ splenocyte homeostasis, effectively correcting the CD4+/CD8+ ratio shift that characterizes immunosenescence (Labunets et al., Bulletin of Experimental Biology and Medicine, 2004, 137:510-512). Interestingly, the peptide’s immunological effects appear age-dependent: in young mice, it suppressed pro-inflammatory cytokine release from macrophages, while in aged animals, macrophage cytokine levels remained unchanged, suggesting context-sensitive rather than uniform immune modulation.
Critical Limitations and Research Gaps
Any honest assessment of the Epithalon literature must address a significant structural limitation: the overwhelming majority of published studies originate from a single research group at the St. Petersburg Institute of Bioregulation and Gerontology, led by Vladimir Khavinson. While the group’s output is prolific and the experimental methodology appears sound within individual papers, independent replication by unaffiliated laboratories has been extremely limited until recently. The 2025 preprint by Al-dulaimi and colleagues at an independent institution represents one of the first external confirmations of Epithalon’s telomere-lengthening activity, making it an important development for the field’s credibility.
No large-scale, randomized, placebo-controlled human clinical trials have been conducted. The existing human data comes from small studies with limited controls. Long-term toxicology data is absent, pharmacokinetic profiling in humans is incomplete, and only the all-L stereoisomeric form has been characterized. The remaining seven stereoisomeric configurations are untested. These gaps mean that while Epithalon’s preclinical profile is robust across multiple endpoints, its translational readiness for clinical application remains premature.
Researchers working with Epithalon should also consider the dual nature of telomerase activation: while beneficial for preventing replicative senescence in healthy cells, telomerase reactivation in pre-malignant cells could theoretically promote tumor progression. The animal tumor data is encouraging (showing reduced tumor incidence), but the mechanistic tension between telomerase activation and oncogenic risk has not been fully resolved in long-term studies.
Relevance for Canadian Peptide Research
For researchers sourcing Epithalon in Canada, verification of peptide identity and purity is essential given the compound’s relatively simple structure and the proliferation of suppliers with varying quality standards. High-performance liquid chromatography (HPLC) analysis should confirm purity above 98%, and mass spectrometry verification of the correct 390.35 Da molecular weight is standard practice. Third-party Certificates of Analysis from accredited laboratories such as Janoshik Analytical provide independent verification that the material matches its stated specifications.
Epithalon should be stored as a lyophilized powder at -20 degrees Celsius for long-term stability. Once reconstituted in sterile bacteriostatic water, aliquots should be stored at 2-8 degrees Celsius and used within a timeframe consistent with peptide stability data, typically within four weeks. Researchers should be aware that the TFA salt form commonly used in synthesis introduces trifluoroacetate counterions that may need to be accounted for in sensitive biological assays.
Those interested in the broader context of COA interpretation and peptide purity verification can review the detailed guide on our research resources page. For researchers exploring the intersection of aging biology and peptide science, our coverage of related compounds such as NAD+ and GHK-Cu, both of which operate through partially overlapping antioxidant and gene expression pathways, may provide useful comparative context. Researchers comparing tissue-repair peptides like BPC-157 and TB-500 will note that Epithalon occupies a distinct mechanistic niche focused on genomic maintenance rather than acute tissue regeneration.
Canadian researchers transitioning from US-based suppliers following the closure of Peptide Sciences in 2026 can source research-grade Epithalon domestically with same-day shipping and full COA documentation through Maple Research Labs.
For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.
For peer-reviewed research on this topic, visit PubMed.
Want more research like this?
Weekly peptide study breakdowns. No spam. Unsubscribe anytime.